Semax

What is Semax?

Semax is a synthetic heptapeptide based on the (4–10) fragment of the hormone adrenocorticotropic hormone (ACTH), modified at the C-terminus with a Pro-Gly-Pro (PGP) tripeptide to slow enzymatic breakdown. Its full sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The peptide was developed in the Soviet Union and Russia (Institute of Molecular Genetics and Moscow State University) and is registered there as a prescription medicine, most commonly as an intranasal solution. Outside Russia and a small number of neighboring countries it has no marketing approval and is encountered only as a research chemical.

Semax is most often discussed in the context of nootropic (cognition-related) and neuroprotective research, with mechanistic work frequently centering on brain-derived neurotrophic factor (BDNF) signaling. It is commonly grouped with the related Russian anxiolytic peptide Selank, which shares the same C-terminal Pro-Gly-Pro motif.

Chemistry and structure

Semax is a short linear peptide. Its key structural features are summarized below.

The first four residues correspond to the ACTH(4–7) region (a sequence shared by ACTH and several melanocortins), while the appended Pro-Gly-Pro "tail" is the engineered feature: prolines flanking the C-terminus markedly reduce cleavage by peptidases, extending the molecule's effective activity relative to the unmodified ACTH fragment. Because of this design, Semax is sometimes written as ACTH(4-7)PGP as well as ACTH(4-10) analog; both descriptions appear in the literature.

Mechanism of action

The mechanism of Semax is not fully established, and several partly independent pathways have been proposed, mostly from animal and in vitro work:

• BDNF / TrkB neurotrophic signaling. The most cited mechanism. In rats, intranasal Semax bound specifically in the basal forebrain and rapidly increased BDNF protein there, and other work links Semax to changes in BDNF and TrkB expression in the hippocampus and cortex. In cerebral-ischemia models, Semax has been reported to activate transcription of neurotrophins (e.g., BDNF, NGF, NT-3) and their receptors.
• Monoaminergic modulation. In rodents, Semax has been reported to influence serotonergic activity (increasing striatal 5-HIAA) and to potentiate amphetamine-driven dopamine release and locomotor effects, suggesting indirect modulation of dopaminergic and serotonergic systems rather than direct receptor agonism.
• Inhibition of enkephalin-degrading enzymes. Semax (and Selank) inhibit enkephalin-degrading enzymes in human serum in vitro (Semax IC50 ≈ 10 µM), which could prolong endogenous regulatory-peptide tone. The clinical relevance of this in vivo is uncertain.
• Melanocortin system. Because Semax shares the ACTH(4–7) core, interactions with melanocortin receptors have been proposed, including reports of antagonism of α-MSH at MC4/MC5 receptors. This remains an area of mechanistic uncertainty rather than a settled pathway.
• Anti-inflammatory / neuroprotective signaling. In ischemia–reperfusion models, proteomic and transcriptomic studies report Semax shifting signaling toward survival and away from cell-death and inflammatory pathways (e.g., reduced phospho-JNK, increased phospho-CREB in some regions).

What does the research show?

The Semax literature is dominated by Russian research groups, and the body of work is unusually concentrated within a small number of affiliated institutions. This is an important interpretive caveat: it limits independent replication and raises the possibility of publication and methodological bias relative to multi-center international programs.

Animal and preclinical evidence

The strongest mechanistic evidence is preclinical. Rodent studies report specific brain binding, rapid BDNF increases, neurotrophin-gene activation after experimental ischemia, monoaminergic modulation, and protein-expression signatures consistent with neuroprotection in middle-cerebral-artery-occlusion models. These findings are internally consistent but were generated largely by the same research lineage.

Human evidence

Human data in the reviewed package are preliminary stroke/neurology reports: small or older samples, sparse blinding/randomization detail by modern standards, and not reproduced by independent Western groups. Cognition/DMN rows above are out-of-package citations, not package-verified findings.

What improved in neurological disease studies?

A 1997 clinical report (PMID 11517472; abstract only) compared 30 patients given Semax with 80 conventionally treated stroke patients said to be comparable in severity/localisation. Authors reported faster recovery of neurological function, especially motor. Randomization and blinding were not verified; between-group effect sizes and confidence intervals are not extractable from the abstract; attrition, co-treatments and funding remain unchecked. Full text was not verified in the 2026-09-15 review package (publishable: false). Source (opens in a new tab). Study card.

A 2007 open study followed 27 patients with motor neuron disease to day 48. The abstract reports improved emotional well-being and motivation, but no effect on denervation, clinical progression or time to marked functional deficits. Better quality of life did not demonstrate slowed disease progression. Full text has not been verified. Source (opens in a new tab). Study card.

The 2018 stroke study included 110 patients. Within early and late rehabilitation groups, allocation to Semax or no Semax was described as randomized. Barthel scores, measuring independence in daily activities, improved faster during the first month; a greater total improvement was reported for late rehabilitation (p=0.044). No corresponding significant total advantage was marked for early rehabilitation. Source (opens in a new tab). Study card.

Blinding and allocation procedures were not adequately described. Late-rehabilitation subgroups differed in time since stroke. Some reported changes do not match subtraction of the table means; no new effect estimate is calculated from these values. Higher blood BDNF is not direct evidence of brain repair.

Clinical and regulatory status

In Russia, Semax has been used clinically since the 1990s, including in acute neurology. This regulatory acceptance is specific to that jurisdiction and does not reflect approval, endorsement, or efficacy confirmation by the FDA, EMA, or comparable agencies.

U.S. FDA — compounding / bulk drug substances (Semax heptapeptide). Outside Russia's marketing authorization, U.S. compounding policy has followed a path similar to several other research peptides: historical placement among substances FDA associated with significant safety concerns under the interim Category 2 503A bulk-substance framework; nominations later appearing among withdrawn listings in the April 2026 update wave (same general batch discussed for BPC-157); and agenda listing for the Pharmacy Compounding Advisory Committee (PCAC) meeting of July 23–24, 2026. A committee discussion or recommendation is not FDA approval to compound, not addition to the final 503A bulks regulation (21 CFR 216.23), and not marketing approval. Exact vote tallies are not hard-coded here pending citation from FDA primary minutes/transcript. Verify current status on FDA.gov compounding pages.

What adverse events were reported?

In the 2018 Semax study, the authors reported no adverse effects and 95% rated tolerability good or very good. There is no detailed event table. The protocol lists tolerability assessments at baseline and months 1 and 2, but not month 5. Five-month efficacy follow-up therefore does not establish five-month structured safety surveillance. The older abstracts do not provide reliable adverse-event rates. Rare events, long-term safety and interactions remain insufficiently characterized. Source (opens in a new tab).

Legal status

Semax is a registered medicine in Russia (and a few neighboring states) and is dispensed there as a pharmaceutical. In the United States it is not an approved drug and is not a scheduled controlled substance; it is typically sold only labeled "for research use" / "not for human consumption." U.S. 503A compounding status for the heptapeptide has been in flux (historical Category 2 concern narrative → withdrawn nomination listings → PCAC July 2026 agenda) and must not be read as permission to compound or as drug approval — see Clinical and regulatory status. In the EU and most other regions it has no marketing authorization. Selling it as, or implying it is, a treatment for any disease is generally not permitted outside its approved jurisdiction. Legal status can vary and change by country; this section is descriptive, not legal advice.

How it compares

Semax is closely paired with Selank: both are short peptides developed in Russia, both append a stabilising Pro-Gly-Pro motif, and both are registered as medicines in Russia but not approved by the FDA or EMA. They differ in emphasis — Semax is studied mainly for nootropic and neuroprotective effects (often via BDNF), while Selank is studied mainly as an anxiolytic. For both, the evidence base is dominated by Russian research that has not been widely replicated in large international trials, so claims should be read with that limitation in mind. See the Cognition, mood & sleep overview.

Common misconceptions

• "Semax is FDA-approved because it's a real drug." It is an approved medicine only in Russia; it has no FDA or EMA approval.
• "The BDNF effect is proven in humans." BDNF effects are best documented in rodents. Direct, replicated human BDNF data are limited.
• "It's been validated in large Western trials." It has not. The evidence base is Russian-dominated and not independently reproduced at scale.
• "As an ACTH fragment, it raises cortisol like ACTH." Semax was selected for neurotropic effects; it is not used as a corticotropic hormone and is not studied for steroid release.
• "Semax and Selank are interchangeable." They share the Pro-Gly-Pro motif and Russian research origin, but differ in sequence and are studied for different primary effects (Semax: nootropic/neuroprotective; Selank: anxiolytic).

Russian research & registry

Semax's regulatory standing is verifiable in the primary register, and much of its clinical evidence is Russian-language and not indexed in the English databases most sites rely on — which is a limit of what those databases reach, not proof the evidence is absent.

• Registry-verified. Semax is registered in the Russian State Register of Medicines (ГРЛС) under registration number LS-002553 (ЛС-002553), marketed by Peptogen as an intranasal solution (0.1% and 1%); the 1% is indicated for the acute period of ischemic stroke. This is a regulatory fact — a 1990s-era Russian approval under a different evidentiary standard — and is not an efficacy confirmation by the FDA, EMA, or a comparable agency.
• [Human] A double-blind, placebo-controlled (placebo: a comparison treatment without the active substance being tested) study in Ophthalmological Bulletin (Oftalmologicheskie Vedomosti), 2014 (Strakhov, Popova, Fedorov), retrieved and translated from CyberLeninka, tested Semax 0.1% intranasal (0.9 mg/kg/day) for one month (study exposure as reported — not a dosing recommendation) in 36 patients (72 eyes; 24 treated, 12 control) with primary open-angle glaucoma, and reported a greater gain in retinal light sensitivity (HRT-perimetry MD +0.83 dB, p<0.05, vs +0.66 in controls), a reduction in corneal Langerhans-cell density (9.1 vs 4.9 cells/mm², p<0.05), and no adverse reactions. Read the design carefully: it is small and single-centre, on a surrogate imaging endpoint in a niche indication — genuine human data pointing in a direction, not a large replicated efficacy trial.

The pattern holds across the Semax literature: registered and used in Russia, studied mostly by Russian groups in small trials, and not replicated in large independent Western RCTs. The registry fact is firm; the efficacy remains Russian-weighted and preliminary — and retrievability is not the same as high-quality evidence.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against the primary sources we could reach. A knowledgeable creator is not peer review, so each statement below was treated as a claim to check, not a fact. One caveat cuts both ways: not locating a supporting study in the databases we searched is not proof that a claim is false. A great deal of relevant work — paywalled journals, Russian and other regional literature, clinical practitioner experience, conference abstracts and unpublished data — is not indexed in the sources available here, so "we couldn't verify this" means exactly that, and no more.

Supported by the sources we could check

• Mixed findings in an Alzheimer mouse model (2025). Semax reduced amyloid plaques and improved novel-object recognition in APP/PS1 mice. Barnes-maze results varied by day: target-finding latency improved on days 2 and 3, but performance deteriorated on day 4. Movement speed also changed. These animal findings do not establish treatment efficacy in people with Alzheimer’s disease. 2025 (opens in a new tab).

Claims that go beyond what we could verify

• "Nasal sprays are bunk — the nasal membrane can't transport it in." This runs against the evidence we do have. Intranasal is Semax's actual registered clinical route in Russia, and radiolabelled peptide appears in rat brain within 2 minutes of intranasal dosing (Shevchenko et al., 2006). The olfactory/trigeminal nose-to-brain pathway is precisely why the intranasal form is used, so a blanket dismissal is hard to square with the pharmacokinetic data.
• "It reverses Alzheimer's, Parkinson's, MS and dementia — it changes the whole hardware." We found no controlled human evidence for disease reversal in the accessible literature — which is a limit of what is indexed there, not proof that no benefit exists. The supportive findings we could locate are animal or in-vitro only (APP/PS1 mice, Radchenko et al. 2025; dopaminergic cell culture, Dolotov et al. 2015), and we found no report of low-dose Semax correcting motor deficits even in animal Parkinson's models. On the sources at hand the honest evidence tags are [Animal]/[In vitro], not [Human]; that is a statement about the evidence we can see, not a verdict that the stronger claim is false.
• "Decades of clinical use in Russia with zero adverse events — one of the safest agents ever developed." This reads as more certain than the evidence available to us allows. Russian studies report good tolerability (how well participants can tolerate adverse effects) at the doses studied, but large-scale, independent, long-term safety data were not found in the sources we searched — their absence here is not the same as a clean safety record. "Zero adverse events" is an absolute that the accessible toxicological record neither establishes nor rules out.
• "Semax upregulates brain glucose transporters, PGC-1α mitochondrial biogenesis, glutathione and neprilysin-driven amyloid clearance." [Hypothesis] These specific molecular mechanisms are stated as settled, but we could not find them demonstrated for Semax in the primary literature we checked — e.g. the 2025 APP/PS1 study measured plaque load and behaviour, not neprilysin, glucose transporters or PGC-1α. That does not mean the pathways are wrong; it means, on the sources reachable here, they are better read as proposed mechanism than as established fact.
• "Alzheimer's is type 3 diabetes," used to imply Semax fixes it. The "type 3 diabetes" framing is a genuine research hypothesis about brain insulin resistance, not (as far as the accessible literature shows) an accepted reclassification. Likewise the Lancet Commission figure cited — ~40% of dementia cases attributable to 12 modifiable risk factors (Livingston et al., Lancet 2020) — is real but concerns lifestyle-based prevention, not Semax. Neither statement, on its own, is evidence of a Semax-specific benefit either way.